Implementation of human stem cell technology in biopharmaceutical R&D
At Pluriomics we are working on the development of a variety of cardiac toxicity and safety pharmacology assays with our mission to facilitate and promote uptake of human stem cell technology in the pharmaceutical industry, in order to improve efficiency in drug discovery and development stages, and to decrease the number of animal use.
To fulfil this mission, Pluriomics has broadened their experience on the application of hiPSC-cardiomyocytes in various stages of drug development. These applications may range from high-throughput screening assays, to electrophysiology assays (e.g. multi-electrode arrays) and more complex applications such as 3D tissue engineering/organ-on-a-chip.
Pluriomics has multiple strategic alliances with technology providers and active research projects in the areas of early cardiac toxicity screening and regulatory screening to be complementary with the new CiPA guidelines. At Pluriomics we find it extremely important to not only supply our well-characterized, quality-controlled, functional hiPSC-cardiomyocytes, but also provide our customers additional services based on the application of (their) hPSC-cardiomyocytes in safety and efficacy cardiac assays. We support our customers from vial to assay. More information on assays we currently support and service can be found here.
Moreover we are always interested to discuss with potential clients about specific assay development projects. For more information, please contact us at email@example.com, or through our contact form below on this webpage. We are happy to answer your questions.
More information on our partners and current collaborating projects can be found here.